Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy

• Status: Completed
• Trial end date: 2005-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

To evaluate activity of gefitinib in subjects with relapsed prostate cancer by estimating PSA response rate at study closure

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Gefitinib

Criteria

Inclusion Criteria:

• Relapsed prostate cancer after prostatectomy or radiotherapy

• PSA levels below 10 ng/mL

• Lymph node negative

• Metastasis negative

• Withdrawal of hormone therapy at least 6 months before entry into the study

• Written informed consent

Exclusion Criteria:

• Metastatic disease

• Hormonal treatment 6 months before study entry

• Concomitant radiotherapy, surgery and/or chemotherapy

• ILD